Skip to search formSkip to main contentSkip to account menu

Acute Promyelocytic Leukemia

Known as: Leukemia, Progranulocytic, AML M3, LEUKEMIA, PROMYELOCYTIC 
An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the t(15;17)(q22;q12) translocation. There are… 
National Institutes of Health

Related topics

Related topics

47 relations
ArsenicBone MarrowBone Marrow Stem Cell with Potential to Differentiate to Granulocytic LineageBone marrow stem cell

Broader (2)

Leukemia, Myelocytic, Acuteleukemia

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Acute promyelocytic leukemia: from highly fatal to highly curable.
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia. Morphologically, it is identified as the M3… 
Highly Cited
1999
Highly Cited
1999
Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
I N THE LATE 1980s and early 1990s, the elucidation of the molecular basis of acute promyelocytic leukemia (APL) emerged as a… 
Highly Cited
1998
Highly Cited
1998
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
BACKGROUND Two reports from China have suggested that arsenic trioxide can induce complete remissions in patients with acute… 
Highly Cited
1997
Highly Cited
1997
Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes
Resveratrol, a phytoalexin found in grapes and other food products, was purified and shown to have cancer chemopreventive… 
Highly Cited
1997
Highly Cited
1997
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
The therapeutic effect of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) was evaluated among 15… 
Highly Cited
1991
Highly Cited
1991
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).
BACKGROUND AND METHODS Patients with acute promyelocytic leukemia have a characteristic (15;17) translocation, with a breakpoint… 
Highly Cited
1990
Highly Cited
1990
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.
Twenty-two patients with acute promyelocytic leukemia were treated with all-trans retinoic acid (RA, 45 mg/m2 per day) for 90… 
Highly Cited
1988
Highly Cited
1988
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.
Twenty-four patients with acute promyelocytic leukemia (APL) were treated with all-trans retinoic acid (45 to 100 mg/m2/day). Of… 
Review
1987
Review
1987
The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.
The HL-60 cell line, derived from a single patient with acute promyelocytic leukemia, provides a unique in vitro model system for… 
Highly Cited
1978
Highly Cited
1978
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.
A human leukemic cell line (designated HL-60) has recently been established from the peripheral blood leukocytes of a patient… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)